Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy

Chung-Feng Huang, Ming-Lung Yu

Clin Mol Hepatol. 2020;26(3):251-260. Published online March 19, 2020

DOI: https://doi.org/10.3350/cmh.2020.0018

View: 14352 Download: 387 Web of Science: 38 Crossref: 41

Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure

Tommaso Lorenzo Parigi, Maria Corina Plaz Torres, Alessio Aghemo

Clin Mol Hepatol. 2019;25(4):360-365. Published online May 2, 2019

DOI: https://doi.org/10.3350/cmh.2019.0022

View: 5436 Download: 242 Web of Science: 9 Crossref: 10

Discussion on critical points for a tailored therapy to cure hepatitis C virus infection

Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo Focà, Carlo Torti

Clin Mol Hepatol. 2019;25(1):30-36. Published online January 23, 2019

DOI: https://doi.org/10.3350/cmh.2018.0061

View: 7599 Download: 152 Web of Science: 14 Crossref: 16

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals

Soon Young Ko, Won Hyeok Choe

Clin Mol Hepatol. 2018;24(4):351-357. Published online March 16, 2018

DOI: https://doi.org/10.3350/cmh.2017.0063

View: 9688 Download: 349 Web of Science: 4 Crossref: 1

2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

Clin Mol Hepatol. 2018;24(3):169-229. Published online August 10, 2018

DOI: https://doi.org/10.3350/cmh.2018.1004

View: 14248 Download: 219 Web of Science: 18 Crossref: 27

Original Article

Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals

Alessio Strazzulla, Giuseppe Coppolino, Giorgio Settimo Barreca, Innocenza Gentile, Laura Rivoli, Maria Concetta Postorino, Maria Mazzitelli, Giuseppe Greco, Chiara Costa, Vincenzo Pisani, Nadia Marascio, Mariadelina Simeoni, Alfredo Focà, Giorgio Fuiano, Daniela Foti, Elio Gulletta, Carlo Torti

Clin Mol Hepatol. 2018;24(2):151-162. Published online April 24, 2018

DOI: https://doi.org/10.3350/cmh.2017.0059

View: 6444 Download: 117 Web of Science: 13 Crossref: 12

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study

Kwang Il Seo, Byung Chul Yun, Weiquan James Li, Sang Uk Lee, Byung Hoon Han, Eun Taek Park

Clin Mol Hepatol. 2017;23(1):74-79. Published online March 3, 2017

DOI: https://doi.org/10.3350/cmh.2016.0052

View: 7502 Download: 147 Web of Science: 2 Crossref: 2

Review

Management of direct antiviral agent failures

María Buti, Rafael Esteban

Clin Mol Hepatol. 2016;22(4):432-438. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0107

View: 11034 Download: 364 Web of Science: 29 Crossref: 27

The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy

Ioannis Varbobitis, George V. Papatheodoridis

Clin Mol Hepatol. 2016;22(3):319-326. Published online September 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0045

View: 13210 Download: 392 Web of Science: 67 Crossref: 68

Original Article

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection

Hee Chul Nam, Hae Lim Lee, Hyun Yang, Myeong Jun Song

Clin Mol Hepatol. 2016;22(2):259-266. Published online June 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0020

View: 9348 Download: 164 Web of Science: 8 Crossref: 7

Review

Chronic hepatitis B in pregnancy: unique challenges and opportunities

Kumaresan Yogeswaran, Scott K. Fung

Clin Mol Hepatol. 2011;17(1):1-8. Published online March 21, 2011

DOI: https://doi.org/10.3350/kjhep.2011.17.1.1

View: 7948 Download: 63 Crossref: 16

1 |

Viewed By 5355	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5302	MAFLD: How is it different from NAFLD?
Viewed By 5204	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3891	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3848	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Search